Duovir is a fixed-dose combination tablet containing Lamivudine (150 mg) and Zidovudine (300 mg), both nucleoside reverse transcriptase inhibitors (NRTIs). Acting synergistically, they inhibit HIV-1 reverse transcriptase, an enzyme essential for viral replication. This suppression leads to reduced viral load, delayed disease progression, and preserved immune function.

Duovir is a core component in first-line ART regimens, often combined with agents like Efavirenz, Dolutegravir, or Tenofovir, and is also recommended in post-exposure prophylaxis (PEP) protocols.

Its fixed-dose format reduces pill burden, enhancing adherence in HIV therapy. Available through a reliable online pharmacy in the Antibiotics & Infections category.

• Antibiotics & Infections | Anti-HIV Drugs / AIDS: Indicated for the treatment of HIV-1 infection in combination with other antiretrovirals.
• Dual-NRTI backbone: Simplifies therapy, reducing resistance risk and improving adherence.
• PEP (Post-Exposure Prophylaxis): Widely used in occupational and nonoccupational settings when initiated within 72 hours after exposure.

• Mechanism: Dual-NRTI synergy inhibits HIV reverse transcriptase and viral replication.
• Immunologic effect: Reduces immune deterioration, slows disease progression.
• Therapeutic role: Backbone of many first-line ART regimens.
• Adherence benefit: Improves treatment adherence via fixed-dose convenience.
• PEP relevance: Plays a key role in emergency PEP protocols.

• General: Take orally with or without food. Adherence is critical to prevent resistance.
• HIV Infection – Adults: 1 tablet twice daily, always with other antiretrovirals.
• Nonoccupational PEP: 1 tablet twice daily for 28 days; start within 72 hours of exposure.
• Occupational PEP: Same as above; start immediately after exposure.
• Pediatrics (≥30 kg): 1 tablet twice daily.
• Under 30 kg: Use separate Lamivudine/Zidovudine formulations.
• Monitoring: Hemoglobin and neutrophil counts should be checked regularly due to Zidovudine’s hematologic toxicity.
• Important: PEP beyond 72 hours post-exposure is less effective. HIV testing before/after therapy is strongly advised.

• Storage condition: Store below 30 °C in a dry place, away from sunlight and moisture.
• Container: Keep container tightly closed, out of reach of children.

• Common: headache, nausea, fatigue, diarrhea.
• Zidovudine-specific: anemia, neutropenia, myopathy with prolonged use.
• Rare: lactic acidosis, hepatomegaly with steatosis.
• Monitoring: Routine blood count monitoring is recommended during extended therapy.